title: A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease.
authors.affiliation: Institute of Pharmacology and Toxicology, Cardarelli Hospital, Naples, Italy.
authors.forename: M G
authors.initials: MG
authors.lastname: Matera
authors.forename: M
authors.initials: M
authors.lastname: Caputi
authors.forename: M
authors.initials: M
authors.lastname: Cazzola
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004359:Drug Therapy, Combination; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D000068299:Salmeterol Xinafoate; D016037:Single-Blind Method
chemical_list: D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D009241:Ipratropium; D000420:Albuterol